Skip to main content
  • Advertise
    Want to Advertise with Us?
    Conquer welcomes advertising and sponsorship collaborations with reputable companies offering high-quality products and services to people affected by cancer.
  • Affiliated Brands
    Academy of Oncology Nurse & Patient Navigators
    The Academy of Oncology Nurse & Patient Navigators (AONN+) is the largest national specialty organization dedicated to improving patient care and quality of life by defining, enhancing, and promoting the role of oncology nurse and patient navigators. Our organization of over 8,900 members was founded in May 2009 to provide a network for all professionals involved and interested in patient navigation and survivorship care services to better manage the complexities of the cancer care treatment continuum for their patients. We view our organization as one consisting of “professional patient advocates” and, to that end, we support and serve our members.
    Journal of Oncology Navigation & Survivorship
    The Journal of Oncology Navigation & Survivorship (JONS) promotes reliance on evidence-based practices in navigating patients with cancer and their caregivers through diagnosis, treatment, and survivorship. JONS also seeks to strengthen the role of nurse and patient navigators in cancer care by serving as a platform for these professionals to disseminate original research findings, exchange best practices, and find support for their growing community.
    The Oncology Nurse-APN/PA
    The Oncology Nurse-APN/PA (TON) provides coverage of the wide spectrum of oncology-related events, trends, news, therapeutics, diagnostics, organizations, and legislation that directly affect hematology/oncology nurses and advanced practitioners involved in healthcare delivery and product utilization. The scope and coverage include a unique presentation of news and events that are shaping the care of patients with cancer.
  • Healthcare Providers
  • Contribute

Libtayo plus Chemotherapy Now FDA Approved for Advanced Lung Cancer without Genomic Alterations

December 2022 Vol 8 No 6

In November 2022, the FDA approved the immunotherapy Libtayo (cemiplimab-rwlc; from Regeneron), a PD-L1 inhibitor, in combination with platinum-based chemotherapy, for the treatment of patients with advanced non–small-cell lung cancer (NSCLC) that does not have EGFR, ALK, or ROS1 genomic aberrations.

The FDA approved Libtayo plus chemotherapy for this indication based on a randomized, multicenter, multinational, double-blind, active-controlled clinical trial of 466 patients with advanced NSCLC who had not received systemic treatment. The patients received either Libtayo plus platinum-based chemotherapy or placebo plus platinum-based chemotherapy.

David R. Gandara, MD
David R. Gandara, MD

“Clearly, this is an advance which is clinically meaningful for our patients with advanced stage non–small-cell lung cancer,” said David R. Gandara, MD, Director, Thoracic Oncology Program, University of California Davis Comprehensive Cancer Center, Sacramento.

Libtayo plus chemotherapy demonstrated significantly longer survival than placebo plus chemotherapy. The average survival was 21.9 months with Libtayo plus chemotherapy versus 13 months with placebo plus chemotherapy. The average time without disease progression was 8.2 months in the Libtayo group versus 5 months in the placebo group. Overall, 43% of patients had a response to Libtayo plus chemotherapy versus 23% in the placebo group.

The most common side effects with Libtayo plus chemotherapy were hair loss, musculoskeletal pain, nausea, fatigue, peripheral neuropathy, and decreased appetite.

Recommended For You